bipolar icd 10
Off-label use of medicines, though acceptable, sometimes it is still controversial in the medical world. Sometimes off-label use is truly justified, in other times it is rarely justified. But how efficient is the U.S. food and regulator of pharmaceuticals, "the FDA," to prevent the promotion inappropriate off-label use of medications?
The well-known phenomenon called "off-label use" refers to the practice of writing prescriptions for drug use beyond the approved scope of a drug. Examples of uses include SSRI medications (approved for depression) prescribed off-label to treat men suffering from premature ejaculation, carbamazepine (anticonvulsant), used to help people with bipolar disorder, and methotrexate or (MTX), which has an approved use for treatment of choriocarcinoma, if often prescribed to manage an outbreak of UN ectopic pregnancy.
In the United States the approval process requires that the Food and Drug Administration (FDA) to be convinced of a drug safety and efficacy in the treatment of disease. Once there is enough convincing evidence, the manufacturer and the FDA to make language prescription label.
But recently a report by the Government Accountability Office (GAO) held that the FDA is about 7 months to send warnings to pharmaceutical companies promoting potentially harmful off-label uses of drugs. And it takes yet another 4 months for these companies to take corrective action in the violations.
The prevalence of off-label prescription can be assessed by the fact that over 20 percent of prescriptions for 100 drugs most used were found to be for use off-label. Moreover, 60 percent of prescriptions were randomly selected to be found again for off-label use.
Hence, is the slow pace of FDA regulation unwanted outside promoting use of the label?
Experts believe it could be to the point enough, due to the following reasons:
1. It takes about 7 to 11 months on average to deal with violations.
2. The FDA does not specifically monitor the promotion of the label. Rather, it is only part of a larger number of monitoring activities to combat all violations promotion. Furthermore, not all submissions to the Agency are under scrutiny, so there is a greater likelihood of violations through the filter.
3. Their ability to control, is not on par with the large volume of material presented (which received 68,000 submissions end in 2007 yes). For example, FDA can manage only a fraction of the thousands of continuing medical education (CME) activities each year, some of which include complaints of doctors identify off-label promotions in the form of statements unsolicited sales people.
4. It does not keep a tab on all submissions, or state examinations support off-label use, that gets in the road outside the control of potential violations.
5. No not a standardized monitoring system for the management of examinations.
6. Some violations by their nature are difficult to track, as violative of the conversations between doctors and representatives of pharmaceutical drugs for sale.
While on one hand, the FDA's Sentinel Initiative is a great program, recently highlighted the shortcomings of the system outside the control of the promotion of drug label does not appear encouraging. In general, seems that the FDA might have to consider a much needed revision of the system to address unauthorized off-label drug promotion, either to the conventional drugs or alternative medicines.
I am a journalist with 7 years of experience. Though, as a professional I’ve reported on myriad topics, my favorites are the auto and the healthcare industry. Two of the platforms I’ve previously worked on are Themedica and Automotive-Online. I now blog at: Smiling Health
Hot Sexy Nymph Butt Grinds Roy
